You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Image of man overlooking city
Power Reimagined

Dovato is indicated for the treatment of HIV-1 in adults and adolescents above 12 years weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.¹

 Learn more about Dovato below

An innovative treatment for your patients living with HIV

Bar chart image
Powerful, Durable Efficacy¹,²
HBR shield image
High Barrier to Resistance²
Pill bottle image
TDF, TAF and ABC Free¹

Dovato Recommended in Treatment Guidelines

EACS Guidelines 2020

Recommended as an initial regimen for treatment-naïve patients and as a switch strategy for virologially suppressed patients⁴

  • Requirements for treatment-naïve patients:
    • HBsAG negative
    • HIV viral load <500,000 copies/mL

DHHS Guidelines 2019

Recommended as an initial regimen for most PLHIV (AI)* as a good option for virologically suppressed patients who have no evidence of resistance to either drug⁵

  • Exclusions for treatment-naïve patients:
    • HIV viral load >500,000 copies/mL
    • HBV co-infection
    • Where ART is to be started before the results of HIV genotype resistance testing for reverse transcriptase or HBV testing are available.

Resources for you and your patients

* Rating of recommendations: A= strong; B= moderate; C= optional. Rating of evidence: I= data from randomised controlled trials; II= data from well-designed non-randomised trials, observational cohort studies with long-term clinical outcomes, relative bioavailability / bioequivalence studies, or regimen comparisons from randomised switch studies; III= expert opinion.⁵

References:

  1. Cahn P, Sierra Madero J, Arribas JR, et al. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-navie adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. J Acquired Immune Defic Syndr. 2020;83(3):310-318.
  2. Van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: Phase 3, randomised noninferioity TANGO study. Clin Infect Dis. 2020. doi:10.1093/cid/ciz1243.
  3. Dovato Summary of Product Characteristics. Available at: https://www.medicines.ie/medicines/dovato-50-mg-300-mg-film-coated-tablets-34871/smpc. Last Accessed October 2021.
  4. European AIDS Clinical Society Guidelines. Version 10.1. October 2020. Last Accessed October 2021.
    https://www.eacsociety.org/guidelines/eacs-guidelines/
  5. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Last Accessed October 2021. Updated December 18, 2019. https://hivinfo.nih.gov/home-page

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Dovato is a registered trade mark of the ViiV Healthcare group of companies or its licensor.

Date of preparation: January 2022 PM-IE-DLL-WCNT-200015